• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞外磷酸盐增强 CFTR 校正剂拯救的 F508del-CFTR 的功能。

Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors.

机构信息

Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom; Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, 78350, Jouy-en-Josas, France.

School of Physiology, Pharmacology and Neuroscience, University of Bristol, Biomedical Sciences Building, University Walk, Bristol, United Kingdom.

出版信息

J Cyst Fibros. 2021 Sep;20(5):843-850. doi: 10.1016/j.jcf.2021.04.013. Epub 2021 May 18.

DOI:10.1016/j.jcf.2021.04.013
PMID:34020896
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8503924/
Abstract

BACKGROUND

The clinical response to cystic fibrosis transmembrane conductance regulator (CFTR) modulators varies between people with cystic fibrosis (CF) of the same genotype, in part through the action of solute carriers encoded by modifier genes. Here, we investigate whether phosphate transport by SLC34A2 modulates the function of F508del-CFTR after its rescue by CFTR correctors.

METHODS

With Fischer rat thyroid (FRT) cells heterologously expressing wild-type and F508del-CFTR and fully-differentiated CF and non-CF human airway epithelial cells, we studied SLC34A2 expression and the effects of phosphate on CFTR-mediated transepithelial ion transport. F508del-CFTR was trafficked to the plasma membrane by incubation with different CFTR correctors (alone or in combination) or by low temperature.

RESULTS

Quantitative RT-PCR demonstrated that both FRT and primary airway epithelial cells express SLC34A2 mRNA and no differences were found between cells expressing wild-type and F508del-CFTR. For both heterologously expressed and native F508del-CFTR rescued by either VX-809 or C18, the magnitude of CFTR-mediated Cl currents was dependent on the presence of extracellular phosphate. However, this effect of phosphate was not detected with wild-type and low temperature-rescued F508del-CFTR Cl currents. Importantly, the modulatory effect of phosphate was observed in native CF airway cells exposed to VX-445, VX-661 and VX-770 (Trikafta) and was dependent on the presence of both sodium and phosphate.

CONCLUSIONS

Extracellular phosphate modulates the magnitude of CFTR-mediated Cl currents after F508del-CFTR rescue by clinically-approved CFTR correctors. This effect likely involves electrogenic phosphate transport by SLC34A2. It might contribute to inter-individual variability in the clinical response to CFTR correctors.

摘要

背景

囊性纤维化跨膜电导调节因子(CFTR)调节剂的临床反应在相同基因型的囊性纤维化(CF)患者之间存在差异,部分原因是通过修饰基因编码的溶质载体的作用。在这里,我们研究了磷酸转运通过 SLC34A2 是否调节 F508del-CFTR 在 CFTR 校正剂挽救后的功能。

方法

我们使用异源表达野生型和 F508del-CFTR 的 Fischer 大鼠甲状腺(FRT)细胞和完全分化的 CF 和非 CF 人气道上皮细胞,研究了 SLC34A2 的表达以及磷酸对 CFTR 介导的跨上皮离子转运的影响。通过用不同的 CFTR 校正剂(单独或组合)孵育或低温处理,将 F508del-CFTR 转运到质膜。

结果

定量 RT-PCR 表明,FRT 和原代气道上皮细胞均表达 SLC34A2 mRNA,并且在表达野生型和 F508del-CFTR 的细胞之间未发现差异。对于用 VX-809 或 C18 挽救的异源表达和天然 F508del-CFTR,CFTR 介导的 Cl 电流的幅度取决于细胞外磷酸盐的存在。然而,在用野生型和低温挽救的 F508del-CFTR Cl 电流中未检测到磷酸盐的这种作用。重要的是,在暴露于 VX-445、VX-661 和 VX-770(Trikafta)的天然 CF 气道细胞中观察到磷酸盐的调节作用,并且该作用依赖于钠和磷酸盐的存在。

结论

在临床上批准的 CFTR 校正剂挽救 F508del-CFTR 后,细胞外磷酸盐调节 CFTR 介导的 Cl 电流的幅度。这种作用可能涉及 SLC34A2 的电致磷酸转运。它可能有助于 CFTR 校正剂临床反应的个体间变异性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f797/8503924/77312763c40a/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f797/8503924/13164a0367b5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f797/8503924/cd914d43d09c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f797/8503924/3c596647e4ae/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f797/8503924/ab73b4a0d60e/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f797/8503924/77312763c40a/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f797/8503924/13164a0367b5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f797/8503924/cd914d43d09c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f797/8503924/3c596647e4ae/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f797/8503924/ab73b4a0d60e/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f797/8503924/77312763c40a/gr5.jpg

相似文献

1
Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors.细胞外磷酸盐增强 CFTR 校正剂拯救的 F508del-CFTR 的功能。
J Cyst Fibros. 2021 Sep;20(5):843-850. doi: 10.1016/j.jcf.2021.04.013. Epub 2021 May 18.
2
Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.三药复方(Trikafta)依利卓艾他康唑/艾美拉唑/卡博替尼(elexacaftor-tezacaftor-ivacaftor)对 F508del 及罕见 CFTR 突变体的别构折叠校正。
JCI Insight. 2020 Sep 17;5(18):139983. doi: 10.1172/jci.insight.139983.
3
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对具有 II 类 CFTR 基因突变(最常见的是 F508del)的囊性纤维化患者的校正治疗(含或不含增效剂)。
Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3.
4
The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor.由于依伐卡托的存在,在人气道上皮细胞中,艾列卡托/替扎卡托/依伐卡托(三联疗法)对F508del-CFTR的挽救作用被低估了。
Eur Respir J. 2022 Feb 24;59(2). doi: 10.1183/13993003.00671-2021. Print 2022 Feb.
5
The F508del-CFTR trafficking correctors elexacaftor and tezacaftor are CFTR-independent Ca-mobilizing agonists normalizing abnormal Ca levels in human airway epithelial cells.F508del-CFTR转运校正剂依列卡福托和替扎卡福托是不依赖CFTR的钙动员激动剂,可使人气道上皮细胞中异常的钙水平正常化。
Respir Res. 2024 Dec 19;25(1):436. doi: 10.1186/s12931-024-03059-8.
6
Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.双校正剂治疗部分挽救 F508del-CFTR 的稳定性和运输缺陷。
Int J Mol Sci. 2021 May 17;22(10):5262. doi: 10.3390/ijms22105262.
7
Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants.靶向 E1 泛素激活酶 (UBA1) 可提高 elexacaftor/tezacaftor/ivacaftor 对 F508del 和罕见错误折叠 CFTR 突变体的疗效。
Cell Mol Life Sci. 2022 Mar 16;79(4):192. doi: 10.1007/s00018-022-04215-3.
8
Lumacaftor inhibits channel activity of rescued F508del cystic fibrosis transmembrane conductance regulator.鲁马卡托抑制挽救型F508del囊性纤维化跨膜传导调节因子的通道活性。
Am J Physiol Lung Cell Mol Physiol. 2025 Jun 1;328(6):L832-L843. doi: 10.1152/ajplung.00287.2024. Epub 2025 May 7.
9
Effect of CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor on lipid metabolism in human bronchial epithelial cells.CFTR调节剂依列卡福/替扎卡福/依伐卡福对人支气管上皮细胞脂质代谢的影响。
Glycoconj J. 2025 Feb;42(1):1-14. doi: 10.1007/s10719-024-10174-7. Epub 2025 Jan 11.
10
The potentiator ivacaftor is essential for pharmacological restoration of F508del-CFTR function and mucociliary clearance in cystic fibrosis.增效剂依伐卡托对于恢复囊性纤维化中F508del-CFTR功能和黏液纤毛清除功能的药理学作用至关重要。
JCI Insight. 2025 Apr 22;10(10). doi: 10.1172/jci.insight.187951. eCollection 2025 May 22.

引用本文的文献

1
Air-Liquid interface cultures to model drug delivery through the mucociliary epithelial barrier.气液界面培养模型用于模拟药物通过黏液纤毛上皮屏障的传递。
Adv Drug Deliv Rev. 2023 Jul;198:114866. doi: 10.1016/j.addr.2023.114866. Epub 2023 May 15.
2
Modifier Factors of Cystic Fibrosis Phenotypes: A Focus on Modifier Genes.囊性纤维化表型的修饰因子:重点关注修饰基因。
Int J Mol Sci. 2022 Nov 17;23(22):14205. doi: 10.3390/ijms232214205.

本文引用的文献

1
Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.三药复方(Trikafta)依利卓艾他康唑/艾美拉唑/卡博替尼(elexacaftor-tezacaftor-ivacaftor)对 F508del 及罕见 CFTR 突变体的别构折叠校正。
JCI Insight. 2020 Sep 17;5(18):139983. doi: 10.1172/jci.insight.139983.
2
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
3
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
在纯合子 F508del 突变的囊性纤维化患者中,elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性:一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
4
ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.ORCAMBI 介导的囊性纤维化原代呼吸培养物黏液清除功能的恢复可通过精氨酸摄取、精氨酸酶抑制和促进一氧化氮信号转导至囊性纤维化跨膜电导调节子通道增强。
Mol Pharmacol. 2019 Oct;96(4):515-525. doi: 10.1124/mol.119.117143. Epub 2019 Aug 19.
5
Augmentation of Cystic Fibrosis Transmembrane Conductance Regulator Function in Human Bronchial Epithelial Cells via SLC6A14-Dependent Amino Acid Uptake. Implications for Treatment of Cystic Fibrosis.通过 SLC6A14 依赖性氨基酸摄取增强人支气管上皮细胞中的囊性纤维化跨膜电导调节剂功能。对囊性纤维化治疗的启示。
Am J Respir Cell Mol Biol. 2019 Dec;61(6):755-764. doi: 10.1165/rcmb.2019-0094OC.
6
Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.VX-809 和 VX-770 对 F508del-CFTR 功能的挽救程度与 F508del/F508del 囊性纤维化患者 SLC26A9 基因中的 SNP rs7512462 相关。
Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1323-1331. doi: 10.1016/j.bbadis.2019.01.029. Epub 2019 Feb 1.
7
Variable Responses to CFTR Correctors : Estimating the Design Effect in Precision Medicine.对CFTR校正剂的可变反应:估算精准医学中的设计效应
Front Pharmacol. 2018 Dec 19;9:1490. doi: 10.3389/fphar.2018.01490. eCollection 2018.
8
Predictive factors for lumacaftor/ivacaftor clinical response.预测 lumacaftor/ivacaftor 临床反应的因素。
J Cyst Fibros. 2019 May;18(3):368-374. doi: 10.1016/j.jcf.2018.12.011. Epub 2018 Dec 28.
9
STRUCTURE, GATING, AND REGULATION OF THE CFTR ANION CHANNEL.CFTR 阴离子通道的结构、门控和调节。
Physiol Rev. 2019 Jan 1;99(1):707-738. doi: 10.1152/physrev.00007.2018.
10
SLC6A14, an amino acid transporter, modifies the primary CF defect in fluid secretion.溶质载体家族 6 成员 14(SLC6A14),一种氨基酸转运蛋白,可改善液体分泌中的原发性 CF 缺陷。
Elife. 2018 Jul 13;7:e37963. doi: 10.7554/eLife.37963.